TR201816532T4 - Spesifik olarak CD38'i tanıyan antikorlar ve bortezomib içeren antitümör kombinasyonları. - Google Patents
Spesifik olarak CD38'i tanıyan antikorlar ve bortezomib içeren antitümör kombinasyonları. Download PDFInfo
- Publication number
- TR201816532T4 TR201816532T4 TR2018/16532T TR201816532T TR201816532T4 TR 201816532 T4 TR201816532 T4 TR 201816532T4 TR 2018/16532 T TR2018/16532 T TR 2018/16532T TR 201816532 T TR201816532 T TR 201816532T TR 201816532 T4 TR201816532 T4 TR 201816532T4
- Authority
- TR
- Turkey
- Prior art keywords
- bortezomib
- antibodies specifically
- specifically recognizing
- containing antibodies
- combinations containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Farmasötik bileşim spesifik olarak CD38'i tanıyan bir antikor ve bortezomib içerir.
Description
Tarifnameye göre bilesimler tercihen parental olarak uygulanabilen bilesimlerdir. Bununla birlikte bu bilesimler lokalize bölgeler terapiler durumunda oral olarak, subkütanöz olarak veya intraperitonal olarak uygulanabilir. Parental uygulamaya yönelik bilesimler genellikle, kullanim zamaninda istege bagli olarak gerekli oldugu kadar hazirlanabilen farmasötik olarak kabul edilebilir, steril solüsyonlar veya süspansiyonlardir. Aköz olmayan solüsyonlar veya süspansiyonlarin hazirlanmasina yönelik olarak zeytinyagi, susam yagi veya sivi petrol gibi dogal bitkisel yaglar veya etil oleat gibi enjekte edilebilir organik esterler kullanilabilir. Steril aköz solüsyonlar su içinde bir ürün solüsyonundan olusabilir. Aköz solüsyonlar, pH degerinin uygun sekilde ayarlanmasi ve solüsyonun örnegin yeterli bir sodyum klorid veya glukoz miktari ile izotonik hale getirilmesi sartiyla intravenöz uygulama için uygundur. Sterilizasyon islemi, isitma yoluyla veya bilesimi olumsuz sekilde etkilemeyen herhangi bir diger sekilde gerçeklestirilebilir. Kombinasyonlar ayrica Iipozomlar formunu veya siklodekstrinler veya polietilen glikoller olarak tasiyicilar ile iliskili formu olabilir. Oral, subkütanöz veya intraperitoneal uygulamaya yönelik bilesimler tercihen aköz süspansiyonlar veya solüsyonlar olabilir. Bulusa göre kombinasyonlarda bilesenlerinin uygulanmasi bir zaman periyodunda es zamanli, ayri veya aralikli olabilir, hümanize anti-CD38 antikor miktarinin kombinasyonun agirliginca %10 ila 90 arasinda bulunmasi özellikle avantajlidir, bu bilesenin iliskili maddenin yapisi, aranan etkinlik ve tedavi edilecek kanserin yapisina göre degiskenlik göstermesi mümkündür. Bulusa göre kombinasyonlar özellikle asagidakiler dahil (ancak bunlarla sinirli olmamak üzere) birkaç kanser türünün tedavisinde faydalidir: karsinom ve adenokarsinom, mesane, meme, kolon, bas ve boyun, prostat, böbrek, karaciger, mide, serviks, tiroid ve deri karsinomlari dahil ve skuamöz hücreli karsinom dahil; Ienfoid soylu hematopoietik tümörler, multipl miyelom, lösemi, akut ve kronik Ienfositik (veya Hodgkin olmayan Ienfoma (örnegin Burkitt) dahil; miyeloid soylu hematopoietik tümörler, akut ve kronik miyelojenöz (miyeloid veya miyelositik) Iösemiler ve promiyelositik lösemi dahil; mezenkimal kökenli tümörler, fibrosarkom, osteosarkom ve rabdomiyosarkom dahil; merkezi ve periferik sinir sistemi tümörleri, astrositom, nöroblastom, gliyom ve schwannomlar dahil ve diger tümörler, melanom, teratokarsinom, kserodermi pigmentosum, keratoakantom ve seminom dahil ve CD38'in ifade edildigi henüz belirlenmedigi diger kanserler. Bunlar çogunlukla, tarifnameye ait anti-CD38 antikorlarinin benzersiz bir hareket mekanizmasina sahip olmasi nedeniyle lösemi, Ienfoma ve yaygin sekilde kullanilan antikanser ajanlarina dirençli kanserlerin tedavi edilmesine yönelik faydalidir. Bir düzenlemede kombinasyonunun antitümör etkinligi yaklasik %11-42 T/C'dir. T/C(%), tedavi edilenin Medyan tümör hacmi / kontrolün Medyan tümör hacmi X 100 olan oranidir. Diger bir düzenlemede kombinasyonunun antitümör etkinligi yaklasik %0-10 T/C'dir. Dolayisiyla, bulusun bir açisi kanserin tedavisinde kullanima yönelik yukaridaki kombinasyonlardir. Diger bir açida, tarifname ayrica kanserin tedavisine yönelik bir ilacin üretilmesine yönelik olarak yukaridaki kombinasyonlarin kullanimini kapsar. Burada açiklanan diger bir düzenleme asagidaki unsurlari içeren bir üretim maddesidir: a) bir ambalajlama materyali b) spesifik olarak CD38li taniyan bir antikor ve en az bortezomibin bir kombinasyonu, burada söz konusu antikor apoptoz, antikor bagimli hücre aracili sitotoksisite (ADCC) ve k0mpleman bagimli sitotoksisite (CDC) yoluyla bir CD38+ hücresini öldürebilir ve c) bunun söz konusu kombinasyonunun kanserin tedavi edilmesine yönelik etkili oldugu belirten, söz konusu ambalajlama materyali içinde bulunan bir etiket veya kullanma talimati. Bu örnekte tümör büyüme inhibisyonuna yönelik bulusa ait bir anti-CD38 antikor/bortezomib kombinasyonunun etkinligi in vivo gösterilmistir. Test Maddesi Uygulamasi: Hu388819 ve Bortezomib tedavileri hücre inokülasyonunundan otuz dört gün sonra baslatilmistir ve dozlar, dozlama öncesinde alinan son ölçümden belirlenen ayri hayvanlarin vücut agirliklarina bagli olarak hesaplanmistir. PBS ve hu388819 antikorunun uygulamasi intraperitoneal (IP) enjeksiyonu yoluyla ve bortezomib intravenöz (IV) enjeksiyon araciligiyla 27 kalibre, V2 inç olan bir igne ile donatilan 1.0 mL'Iik bir siringa kullanilarak kuyruk damari vasitasiyla gerçeklestirilmistir. Spesifik Çalisma Tasarimi: NCl-H929 multipl miyelom subkütanöz ksenogreft modeli fare basina 1 X 107 hücre olan subkütanöz enjeksiyon araciligiyla disi CB.17 SCID farelerde baslatilmistir, 0.1 ml serum-içermeyen kültür ortaminda süspanse edilmistir. Tümör hücre inokülasyonundan otuz-üç gün sonra, altmis-dört fare tümör hacmi (19.4 ± 1.1, Medyan ± SD) gram arasinda olmustur. Her gruptaki fareler kulaktaki bir delik ile tanimlanmistir. Tedavi gruplari PBS kontrolü (, hu3BSB19 antikoru (5.0 kombinasyon grubu (5.0 mg/kg/tedavi) ve bortezomib (1.0, 0.6 ve 0.4 mg/kg/tedavi) içermistir. PBS, hu38SB19 ve borteZOmib bir hafta boyunca haftada iki kez uygulanmistir (toplamda 2 tedavi boyunca günler 34 ve 37). Tedaviler tümör hücrelerinin inokülasyonu sonrasinda 34"üncü günde baslatilmistir. Tümör hacimleri bir kaliper kullanilarak üç boyutlu olarak haftada bir ila iki kez ölçülmüstür. Tümör hacmi asagidaki formül kullanilarak mm3 (veya mg) cinsinden ifade edilmistir: V = Uzunluk X Genislik X Yükseklik X 1/2. Vücut agirliklari test ajani toksisitesinin yaklasik bir indeksi olarak haftada iki kez ölçülmüstür. Tümör hacmi ve vücut agirligi Labcat yazilimi araciligiyla belirlenmistir ve kaydedilmistir. Sonuçlar: hu388819 antikoru ve bortezomibin tek basina ve kombinasyon halinde anti-tümör aktivitesi, subkütanöz NCI-H929 tümör ksenogreftlari, bir insan multipl miyelom modeli tasiyan disi SCID farelerde degerlendirilmistir. Asagidaki uç noktalar kullanilmistir: Toksisite, 2 %20 vücut agirligi kaybi veya 2 %10 ilaç ölümünü indükleyen dozajlarda belirtilmistir, Antitümör etkinligi asagidaki unsurun hesaplanmasi araciligiyla belirlenmistir: T/C (70) = Tedavi edilenin medyan tümör hacmi 1 Kontrolün medyan tümör hacmi X 1 00, burada bir TIC s %42 durumu, anti-tümör aktivitesinin minimum seviyesidir. T/C TR TR TR TR TR TR TR TR TR
Claims (1)
1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10306395 | 2010-12-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201816532T4 true TR201816532T4 (tr) | 2018-11-21 |
Family
ID=44168449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2018/16532T TR201816532T4 (tr) | 2010-12-10 | 2011-12-08 | Spesifik olarak CD38'i tanıyan antikorlar ve bortezomib içeren antitümör kombinasyonları. |
Country Status (42)
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2191843A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
| LT2621531T (lt) | 2010-09-27 | 2017-04-10 | Morphosys Ag | Anti-cd38 antikūnas ir lenalidomidas arba bortezomibas, skirti išsėtinės mielomos ir nhl (nehodžino limfoma) gydymui |
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| HUE036518T2 (hu) | 2012-09-25 | 2018-07-30 | Morphosys Ag | Kombinációk és alkalmazásaik |
| SG11201506956TA (en) | 2013-03-13 | 2015-10-29 | Sanofi Sa | Compositions comprising anti-cd38 antibodies and carfilzomib |
| WO2015014659A1 (en) * | 2013-08-02 | 2015-02-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-claudin 1 antibodies and uses thereof |
| ES2825625T3 (es) * | 2013-10-31 | 2021-05-17 | Sanofi Sa | Anticuerpos anti-CD38 específicos para tratar cánceres humanos |
| EP3063173B1 (en) * | 2013-10-31 | 2020-07-29 | Sanofi | Specific anti-cd38 antibodies for treating human cancers |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US10617757B2 (en) | 2014-08-08 | 2020-04-14 | The Regents Of The University Of California | Methods for treating multiple myeloma |
| MY192918A (en) | 2014-09-09 | 2022-09-15 | Janssen Biotech Inc | Combination therapies with anti-cd38 antibodies |
| EP3227338A4 (en) | 2014-12-04 | 2018-05-16 | Janssen Biotech, Inc. | Anti-cd38 antibodies for treatment of acute myeloid leukemia |
| CR20170526A (es) | 2015-05-20 | 2018-04-03 | Janssen Biotech Inc | ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38 |
| MY192978A (en) | 2015-06-22 | 2022-09-20 | Janssen Biotech Inc | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| PL3827845T3 (pl) | 2015-11-03 | 2022-07-11 | Janssen Biotech, Inc. | Formulacje podskórne przeciwciał anty-cd38 i ich zastosowania |
| BR112019000544A2 (pt) | 2016-07-15 | 2019-04-24 | Takeda Pharmaceutical Company Limited | métodos e materiais para avaliar resposta a terapias de plasmoblasto- e depleção celular plasmática |
| CN110997722B (zh) | 2017-06-08 | 2023-09-26 | 黑带医疗有限公司 | Cd38调节抗体 |
| JP7679196B2 (ja) | 2017-06-08 | 2025-05-19 | ブラック ベルト セラピューティクス リミテッド | Ｃｄ３８調節抗体 |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| CA3072296A1 (en) * | 2017-08-16 | 2019-02-21 | Black Belt Therapeutics Limited | Cd38 antibody |
| CN111032693B (zh) | 2017-08-16 | 2023-09-26 | 黑带医疗有限公司 | Cd38调节抗体 |
| US11542338B2 (en) | 2017-08-16 | 2023-01-03 | Black Belt Therapeutics Limited | CD38 modulating antibody |
| CA3079242A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
| AU2019208102B2 (en) | 2018-01-12 | 2025-10-09 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-CD38 antibodies |
| US20210155708A1 (en) * | 2018-07-10 | 2021-05-27 | Sanofi | Combination therapies against cancer targeting cd38 and tgf-beta |
| US11655302B2 (en) | 2019-06-10 | 2023-05-23 | Sanofi | Anti-CD38 antibodies and formulations |
| CN115698064A (zh) | 2019-12-05 | 2023-02-03 | 赛诺菲-安万特美国有限责任公司 | 用于皮下施用的抗cd38抗体的配制品 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB750155A (en) | 1953-03-17 | 1956-06-13 | Nat Res Dev | Substituted alanines |
| US3032585A (en) | 1954-12-03 | 1962-05-01 | Nat Res Dev | Process for the production of p-bis-(2-chloroethyl)-aminophenylalanine |
| US3116282A (en) | 1960-04-27 | 1963-12-31 | Upjohn Co | Pyrimidine nucleosides and process |
| US4281061A (en) * | 1979-07-27 | 1981-07-28 | Syva Company | Double antibody for enhanced sensitivity in immunoassay |
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| BRPI9809391B8 (pt) | 1997-04-14 | 2021-05-25 | Amgen Res Munich Gmbh | processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| JP2003524587A (ja) | 1998-06-05 | 2003-08-19 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | 多発性骨髄腫を処置するための、ｃｄ３８に対する、遺伝子操作した抗体の使用 |
| DE19826517B4 (de) | 1998-06-15 | 2006-03-23 | Baxter Healthcare S.A. | Verfahren zur Herstellung von Filmtabletten mit Cyclophosphamid als Wirkstoff und daraus hergestellte Cyclophosphamid-Filmtablette |
| US7223397B1 (en) | 1999-01-07 | 2007-05-29 | Research Development Foundation | Potentiation of anti-CD38-Immunotoxin cytotoxicity |
| GB0221574D0 (en) | 2002-09-17 | 2002-10-23 | Isis Innovation | Treatments |
| JP2008504013A (ja) | 2004-02-06 | 2008-02-14 | モルフォシス・アクチェンゲゼルシャフト | 抗ｃｄ３８ヒト抗体及びその用途 |
| JP4912597B2 (ja) | 2004-07-13 | 2012-04-11 | パナソニック株式会社 | 液晶表示装置 |
| US20080057070A1 (en) | 2004-11-04 | 2008-03-06 | Chiron Corporation | Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use |
| EA015584B1 (ru) | 2005-03-23 | 2011-10-31 | Генмаб А/С | Антитело к cd38 человека и его применение |
| HRP20191115T1 (hr) * | 2006-09-26 | 2019-09-20 | Genmab A/S | Anti-cd38 u kombinaciji s kortikosteroidima zajedno s jednim ne-kortikosteroidnim kemoterapeutikom za liječenje tumora |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| SI2195023T1 (en) | 2007-08-29 | 2018-07-31 | Sanofi | Humanized anti-CXCR5 antibodies, their derivatives and their uses |
| AU2009206506B2 (en) | 2008-01-23 | 2013-01-10 | Xencor, Inc. | Optimized CD40 antibodies and methods of using the same |
| EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| EP2191843A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
| EP2191841A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
| EP2191842A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
| LT2621531T (lt) * | 2010-09-27 | 2017-04-10 | Morphosys Ag | Anti-cd38 antikūnas ir lenalidomidas arba bortezomibas, skirti išsėtinės mielomos ir nhl (nehodžino limfoma) gydymui |
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| US8542056B2 (en) * | 2010-12-27 | 2013-09-24 | Stmicroelectronics S.Rl. | High voltage transmission switch, namely for ultrasound applications |
| US10342869B2 (en) | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| UA118255C2 (uk) | 2012-12-07 | 2018-12-26 | Санофі | Композиція, яка містить антитіло до cd38 і леналідомід |
| SG11201506956TA (en) | 2013-03-13 | 2015-10-29 | Sanofi Sa | Compositions comprising anti-cd38 antibodies and carfilzomib |
| EP3063173B1 (en) | 2013-10-31 | 2020-07-29 | Sanofi | Specific anti-cd38 antibodies for treating human cancers |
-
2011
- 2011-08-12 UA UAA201308680A patent/UA112170C2/uk unknown
- 2011-12-07 AR ARP110104584A patent/AR084196A1/es unknown
- 2011-12-08 CN CN201610701653.1A patent/CN106334187B/zh active Active
- 2011-12-08 SG SG2013044144A patent/SG191059A1/en unknown
- 2011-12-08 TR TR2018/16532T patent/TR201816532T4/tr unknown
- 2011-12-08 US US13/992,684 patent/US9314522B2/en active Active
- 2011-12-08 EA EA201390850A patent/EA026406B1/ru not_active IP Right Cessation
- 2011-12-08 KR KR1020137017923A patent/KR101905208B1/ko active Active
- 2011-12-08 CA CA2820382A patent/CA2820382C/en not_active Expired - Fee Related
- 2011-12-08 ES ES11801669.0T patent/ES2694784T3/es active Active
- 2011-12-08 MA MA36092A patent/MA34816B1/fr unknown
- 2011-12-08 EP EP11801669.0A patent/EP2648747B1/en active Active
- 2011-12-08 HR HRP20181787TT patent/HRP20181787T1/hr unknown
- 2011-12-08 BR BR112013014370-3A patent/BR112013014370B1/pt active IP Right Grant
- 2011-12-08 AU AU2011340472A patent/AU2011340472B2/en active Active
- 2011-12-08 MY MYPI2013002090A patent/MY165109A/en unknown
- 2011-12-08 PL PL11801669T patent/PL2648747T3/pl unknown
- 2011-12-08 LT LTEP11801669.0T patent/LT2648747T/lt unknown
- 2011-12-08 PT PT11801669T patent/PT2648747T/pt unknown
- 2011-12-08 SG SG10201600985XA patent/SG10201600985XA/en unknown
- 2011-12-08 WO PCT/EP2011/072228 patent/WO2012076663A1/en not_active Ceased
- 2011-12-08 MX MX2017001016A patent/MX393853B/es unknown
- 2011-12-08 EA EA201692047A patent/EA201692047A1/ru unknown
- 2011-12-08 NZ NZ612055A patent/NZ612055A/en unknown
- 2011-12-08 EP EP18180404.8A patent/EP3412311A1/en not_active Withdrawn
- 2011-12-08 PE PE2013001392A patent/PE20140004A1/es active IP Right Grant
- 2011-12-08 HU HUE11801669A patent/HUE039893T2/hu unknown
- 2011-12-08 MX MX2013006566A patent/MX345257B/es active IP Right Grant
- 2011-12-08 JP JP2013542546A patent/JP6177133B2/ja active Active
- 2011-12-08 RS RS20181352A patent/RS57997B1/sr unknown
- 2011-12-08 CN CN201180064549.1A patent/CN103282050B/zh active Active
- 2011-12-08 SI SI201131609T patent/SI2648747T1/sl unknown
- 2011-12-08 PH PH1/2013/501183A patent/PH12013501183A1/en unknown
- 2011-12-08 DK DK11801669.0T patent/DK2648747T3/en active
- 2011-12-09 TW TW100145632A patent/TWI596116B/zh active
- 2011-12-09 UY UY0001033791A patent/UY33791A/es not_active Application Discontinuation
-
2013
- 2013-06-05 IL IL226756A patent/IL226756B/en active IP Right Grant
- 2013-06-06 NI NI201300050A patent/NI201300050A/es unknown
- 2013-06-06 GT GT201300147A patent/GT201300147A/es unknown
- 2013-06-06 CO CO13137654A patent/CO6801634A2/es not_active Application Discontinuation
- 2013-06-07 TN TNP2013000245A patent/TN2013000245A1/fr unknown
- 2013-06-07 EC ECSP13012669 patent/ECSP13012669A/es unknown
- 2013-06-07 CR CR20130270A patent/CR20130270A/es unknown
- 2013-06-10 CL CL2013001670A patent/CL2013001670A1/es unknown
- 2013-06-10 DO DO2013000132A patent/DOP2013000132A/es unknown
- 2013-06-28 ZA ZA2013/04845A patent/ZA201304845B/en unknown
-
2018
- 2018-11-08 CY CY20181101180T patent/CY1121179T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201816532T4 (tr) | Spesifik olarak CD38'i tanıyan antikorlar ve bortezomib içeren antitümör kombinasyonları. | |
| ES2617689T3 (es) | Combinación terapéutica que comprende un inhibidor de PLK1 y un agente antineoplásico | |
| CN102264385A (zh) | 含特异性识别cd38的抗体和苯丙氨酸氮芥的抗肿瘤组合 | |
| RU2013120311A (ru) | Терапевтическое применение агониста tlr и комбинированная терапия | |
| US8388963B2 (en) | Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof | |
| ES2625492T3 (es) | Combinación terapéutica que comprende un inhibidor de Cdc7 y un agente antineoplásico | |
| TR201807070T4 (tr) | Kemoterapi öncesinde veya başlamasıyla birlikte parenteral balık yağı/DHA +EPA uygulaması. | |
| BR112019021393A2 (pt) | imunoterapia combinada contra o câncer com o complexo de anel macrocíclico penta-aza | |
| JP2018193302A (ja) | ペンタアザ大環状環複合体による組み合わせ癌免疫療法 | |
| EA201892797A1 (ru) | Наночастицы для доставки лекарственных средств и способы лечения лекарственно-резистентного рака | |
| CN109498627B (zh) | 一种治疗肿瘤的药物组合物及其应用 | |
| CN106267213A (zh) | 环二核苷酸cGAMP在治疗肿瘤联合用药中的应用 | |
| Reeves et al. | Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice | |
| TW202435896A (zh) | 包含阿茲夫定和化療試劑的抗腫瘤藥物組合物 | |
| JP5881782B2 (ja) | 医薬組成物又は組合せ剤 | |
| KR101851820B1 (ko) | 치료적 요법 | |
| EP3765080A1 (en) | Improvements in cd47 blockade therapy by egfr antibody | |
| CN109420167A (zh) | 一种治疗肿瘤的联合用药物 | |
| Koide et al. | Antitumor effect of gold as revealed by growth suppression of cultured cancer cells | |
| CN115227690B (zh) | 土木香内酯在双表达型b细胞淋巴瘤中的应用 | |
| JP2021533107A (ja) | 癌を治療するための併用療法 | |
| Mir et al. | Targeted Therapies in Combination with Metronomic Chemotherapy | |
| EP4591868A1 (en) | Medicament for preventing and treating tumor and use thereof | |
| JPH0211513A (ja) | 制癌剤 | |
| Vogler | Clinical trials of 1‐β‐D‐arabinofuranosyl cytosine and 1, 3‐bis‐(2‐chloroethyl)‐1‐nitrosourea combination in metastatic cancer and acute leukemia |